Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from BioArctic AB Class B ( ($SE:BIOA.B) ).
BioArctic AB’s partner, Eisai, has initiated a rolling submission of a Supplemental Biologics License Application to the U.S. FDA for Leqembi Iqlik, a subcutaneous autoinjector for early Alzheimer’s disease treatment, under Fast Track status. This development could allow patients to receive treatment at home, offering a more convenient alternative to intravenous dosing, potentially reducing healthcare resource demands and streamlining Alzheimer’s treatment.
The most recent analyst rating on ($SE:BIOA.B) stock is a Hold with a SEK291.00 price target. To see the full list of analyst forecasts on BioArctic AB Class B stock, see the SE:BIOA.B Stock Forecast page.
More about BioArctic AB Class B
BioArctic AB is a biopharmaceutical company focused on developing treatments for neurodegenerative diseases, particularly Alzheimer’s disease. The company is known for its collaboration with Eisai in developing lecanemab, a monoclonal antibody targeting amyloid-beta, which is a hallmark of Alzheimer’s disease.
Average Trading Volume: 224,732
Technical Sentiment Signal: Buy
Current Market Cap: SEK26.79B
For a thorough assessment of BIOA.B stock, go to TipRanks’ Stock Analysis page.